VIDO

2024-25 ANNUAL REPORT

50 YEARS

UNIVERSITY OF SASKATCHEWAN

For half a century, the **University of Saskatchewan**'s (USask) **Vaccine and Infectious Disease Organization** (VIDO), has been a world leader in infectious disease research and vaccine development for humans and animals.

With a rich history of innovation, cutting-edge infrastructure and unmatched expertise, VIDO remains a source of pride for Canada. As **Canada's Centre for Pandemic Research**, we are committed to developing solutions for emerging infectious diseases, ensuring a healthier, safer world for the future.

VIDO | 2024-25 ANNUAL REPORT

TABLE OF CONTENTS

A global team united from over 35 countries, driving innovation in infectious disease research and vaccine development.

Vision

Healthy People,
Healthy Animals

Mission

To protect the world from infectious diseases.

Values

Excellence
We bring relentless passion for progress and meaningful impact every day, as we strive to be known as global thought leaders and innovators.

Commitment
We are purpose driven, committed to being the best we can be, constantly working to improve ourselves, to cultivate our knowledge and attitudes and to achieve positive change.

Respect
We strive for inclusivity and exhibit deferential regard for all manners of diversity and value the talents and beliefs of our clients, partners, and colleagues.

Team
We understand that success lies in our ability to trust each other, behaving with integrity through constructive collaboration, we support one another in the achievement of a common vision.

Accountability
We proactively focus on solutions and results by engaging others in decisions and plans that involve them, and collectively commit to those decisions.

MESSAGE FROM THE CHAIR

Celebrating 50 years of impact and innovation

As we mark VIDO's 50th anniversary, I am proud of how far we have come and even more excited about where we are headed. From our early days as a pioneering research facility focused on animal health to becoming Canada's Centre for Pandemic Research, VIDO has consistently delivered world-class science with a lasting impact on global health.

This year, we have continued building on that legacy. Our growing expertise in high-containment research, large animal models, and vaccine manufacturing ensures we remain at the forefront of infectious disease preparedness.

Later this year, we will host the Healthy People, Healthy Animals Scientific Symposium, bringing together global leaders in infectious disease research. It's an opportunity to share what we have achieved and highlight what comes next as we work to protect people, animals, and food security.

On behalf of the Board, I extend my gratitude to the VIDO team, as well as our partners and supporters, for their continued commitment to advancing our mission of creating a healthier world.

Amy Cronin
Chair, Board of Directors

BOARD OF DIRECTORS

In order left to right:

Francisco Diaz-Mitoma – Canada (ON)

Volker Gerdts (CEO & Director) – Canada (SK)

Heather Davis – Canada (ON)

Jeremy Gowler – United States

Amy Cronin – Canada (ON)

Duane Thompson – Canada (SK)

Kari Harvey – Canada (SK)

Baljit Singh – Canada (SK)

Dieter Schillinger – Germany

Missing:

Gillian Muir – Canada (SK)

J. Mark Lievonen – Canada (ON)

Preston Smith – Canada (PEI)

Ryan Thompson – Canada (SK)

MESSAGE FROM THE DIRECTOR AND CEO

A legacy of impact: Shaping the future of global health

As we plan to celebrate VIDO's 50th anniversary, I find myself reflecting on the incredible journey that has shaped who VIDO is today. Over five decades, VIDO has evolved from a pioneering animal health research institute into a global leader in infectious disease research and vaccine development. In this time, the world has witnessed tremendous advances in science, especially in the field of vaccines, and VIDO played a key role in contributing to this progress.

From our early research on calf scours to tackling Highly Pathogenic Avian Influenza (HPAI) in dairy cattle, or our advancements in pan-coronavirus vaccine technologies, our journey has been defined by constant innovation.

The world has changed dramatically since 1975, and the field of vaccine research has seen breakthroughs that we could only dream of when VIDO first began. From the advent of genetic-based vaccines to the worldwide response to COVID-19, scientific research has been essential in addressing the ever-changing challenges and opportunities in global health. Scientific research continues to play a crucial role in shaping a healthier world, and VIDO's vision of providing solutions through research has never been more important.

As we look to the future, I am filled with confidence in VIDO's ability to meet the next global health threat. The work we do today has the potential to prevent the spread of deadly diseases, protect livestock, and ensure food security for future generations. VIDO will continue to be at the forefront of the response, thanks to the dedication of our talented team and the ongoing support from our partners.

Our 50th anniversary is not just a celebration of our past, but a call to action for the future. We will continue to grow our partnerships, attract the brightest minds, and advance our research so that we can make an even greater impact. The road ahead is full of possibilities, and together with our supporters, we will continue to shape a healthier, more secure world for generations to come.

None of this would have been possible without the generous support of the Government of Canada, the Government of Saskatchewan, the City of Saskatoon, and our dedicated individual and corporate donors—the Friends of VIDO. Thank you for being part of this remarkable journey, and for standing with us as we continue our vital work to improve health across the globe.

Together, we've accomplished so much, but the best is yet to come.

Volker Gerdts
Director and CEO

LEADERSHIP TEAM

In order left to right:

Jose Rodriguez – Director of Business Development

Volker Gerdts – Director and CEO

Jordan Hamel – Director of Human Resources

Cam Ewart – Director of Facilities

Andrew Van Kessel – Director of Research

Trina Racine – Director of Vaccine Development

Lorne Vanin – Director of Finance

Paul Hodgson – Director of Operations

2024-2025
COMMUNITY LIAISON COMMITTEE REPORT

The Community Liaison Committee (CLC) is an example of the best practices for containment facilities worldwide.

Comprised of community leaders, the committee's role is to provide oversight and information to the public regarding safety and security. The committee helps create and maintain an atmosphere of trust, confidence, and transparency with the public.

CLC was created by the USask to independently serve to ensure full and open communication on safety issues related to VIDO.

In the 2024-2025 fiscal year, the CLC received reports of six incidents, only one of which involved potential exposure to risk group 3 pathogen. It was later confirmed no exposure occurred. All incidents were resolved to the satisfaction of the committee with no risk to the public. These resolutions included staff retraining, equipment replacement and procedure changes. We received regular reports on security and communications. In addition, we have completed both conflict of interest and confidentiality policies.

Dr. Scott Napper and Dr. Volker Gerdts made presentations at our community meeting in June 2024. The 2025 event was held May 26 at the Willows in Saskatoon, Sask., with presentations by Drs. Yan Zhou and Antonio Facciolo on HPAI, and by Dr. Gerdts on an update of the containment level 4 upgrade. The committee follows current issues by regular briefings from scientists at our meetings.

The CLC is grateful to the staff for their support of the committee to help us fulfil our mandate. The committee has a website (www.vidoclc.ca) and members of the public can contact the committee at vidoclc@usask.ca.

We will continue to monitor the community for potential issues worldwide as well as regarding VIDO as Canada's Centre for Pandemic Research.

Susan Lamb
Chair, Community Liaison Committee

2024-2025 CLC MEMBERS:

Simon Kapaj, Patricia Roe, Sarina Gersher, Dick Batten, Robin Chapman, Susan Lamb, Brian Gibbs, Volker Gerdts

Not pictured: Vance McNab, Noreen Jeffrey, Doug Wegren, Tracey Thue (ex-officio), Stacy Strom (ex-officio), Heather Persson (ex-officio), and Kelly Richmond (ex-officio)

10-Year Transformation Roadmap

VIDO has a vision for our future and a new 10-year roadmap to guide this transformation. This roadmap will help ensure our organization remains a global leader for emerging infectious diseases.

TO REACH THIS WE WILL FOCUS ON THE FOLLOWING PRIORITIES:

#1 PEOPLE AND CULTURE

Enhance leadership capabilities throughout VIDO that embrace inclusivity and promote an entrepreneurial team culture to ensure organizational viability

#2 ORGANIZATIONAL EXCELLENCE

Deliver scientific excellence that consistently supplies products and services that meet stakeholder needs

#3 INFRASTRUCTURE AND CAPACITY CREATION

Establish world-class research capacity that positions Canada as a leader in the response to global emerging diseases and pandemics

#4 BUSINESS DEVELOPMENT

Establish a robust business development model, and build global strategic partnerships to secure long-term value creation for stakeholders

CANADA'S CENTRE FOR PANDEMIC RESEARCH

VIDO is building one of the most advanced infectious disease research centres in the world, designed to accelerate the development of vaccines and treatments that protect both human and animal health.

With the ability to study any pathogen, including those requiring the highest level of containment, VIDO is helping Canada and the world prepare for future pandemics. The facility brings together everything needed to develop vaccines and treatments under one roof: from early discovery through to testing and in-house manufacturing. By working with leading partners across Canada and around the globe, VIDO is creating faster, more coordinated responses to emerging threats.

READY FOR ANY PATHOGEN

VIDO's facilities range from containment level 2 to level 4 (currently under construction), enabling safe research on all types of pathogens from familiar viruses and bacteria to newly emerging threats affecting people and animals.

DESIGNED FOR EVERY SPECIES

Purpose-built facilities support research in a wide range of animals, from livestock and wildlife to insects, bats, exotic species and non-human primates, allowing more accurate disease models and faster progress toward real-world solutions.

FROM DISCOVERY TO DELIVERY

VIDO combines research, testing, and vaccine manufacturing together in one location. This seamless vertical approach speeds up the development of vaccines and treatments for both human and veterinary use.

BUILT FOR CANADA, CONNECTED TO THE WORLD

A key part of Canada's Biomanufacturing and Life Sciences Strategy, VIDO works with global leaders like CEPI, WHO, and NIH to improve pandemic preparedness and response worldwide.

CANADA'S LARGEST HIGH CONTAINMENT FACILITY

Equivalent in size to **2.5 football fields**

Includes **18 CL3 animal rooms** and **7 CL3 laboratories**

Tested over **500 new COVID-19 treatments**

Being **upgraded to CL4** to study any infectious disease

VACCINE DEVELOPMENT CENTRE

Produces **all major vaccine** platforms

Develops vaccines for **both human and animal** use

CL3 capable for high-containment vaccine work

NEW CL2 ANIMAL HOUSING

6 times more animal housing space than current capacity

Expanded capacity for species like **bats**, **ticks**, and **bison**

CL2 MODERNIZATION

Upgrading original labs to meet **modern CL2 standards**

Centralized core labs for **microscopy** and **flow cytometry**

PEOPLE & CULTURE

At the heart of VIDO's success is its people with the team bringing together the expertise and dedication needed to lead Canada—and the world—in preparing for and responding to future pandemics, ensuring food security, and advancing the health of both humans and animals.

A key priority for VIDO is cultivating a highly engaged team that lives the organization's core values: Excellence, Commitment, Respect, Teamwork, and Accountability. As VIDO builds for the future, it is actively expanding its scientific capacity by recruiting new researchers, strengthening collaborative networks, and training the next generation of scientific leaders.

Trainees remain the largest and most dynamic group at VIDO, playing a vital role in the organization's mission. In 2024–25, VIDO hired 42 summer students, honours students, interns, graduate students, and postdoctoral fellows across a range of disciplines.

VIDO invested in professional development opportunities that empowered team members to grow both personally and professionally. This included leadership development and anti-racism/anti-oppression training, creating pathways for individuals to thrive and contribute meaningfully to collective goals.

To foster a connected and engaged workplace, VIDO hosts three all-staff meetings annually, distributes a bi-monthly internal newsletter, and organizes regular social events—including its much-anticipated curling, bowling, and golf tournaments.

Recognizing that diverse teams drive innovation, VIDO is committed to increasing representation from under-represented equity groups and creating an inclusive environment where everyone can thrive.

VIDO's ambitious vision for the future will be realized through its most valuable asset: our people.

MORE THAN
215
STAFF & TRAINEES

FROM
35
COUNTRIES

ORGANIZATIONAL EXCELLENCE:
HUMAN AND ANIMAL HEALTH

High-priority infectious diseases, such as foreign animal diseases and potential future threats like "Disease X" pose ongoing risks to both human and animal health. "Disease X" is the term used by scientists and the World Health Organization (WHO) to describe an unknown pathogen that could emerge and cause a serious international epidemic or pandemic.

VIDO's research is focused on accelerating the development of effective vaccines and therapeutics for these critical threats. This work supports global health preparedness by enabling faster, more coordinated responses that can help save lives.

Central to this effort is VIDO's high-containment infrastructure, including the upcoming addition of containment level 4 (CL4) facility. Once complete, CL4 capabilities will allow VIDO to work with any pathogen, including those that cause diseases like Lassa fever and Hantavirus Pulmonary Syndrome. By combining high-containment research with expertise in animal modeling and vaccine development, VIDO is well-positioned to address today's threats while preparing for the challenges of tomorrow.

More information about the full scope and impact of VIDO's ongoing projects is available at **vido.org/research**.

Pioneering Next-Generation Research

The highlights on the following pages showcase a selection of VIDO's current research and development activities.

UNDERSTANDING AND CONTAINING HANTAVIRUS

Hantaviruses cause severe and often fatal infections in humans. In North America, Sin Nombre virus (SNV) is the primary cause of hantavirus pulmonary syndrome (HPS), a disease with a high fatality rate and no available vaccines or effective treatments. HPS progresses rapidly, causing acute respiratory distress that is difficult to manage.

VIDO is tackling this threat from multiple angles. Dr. Bryce Warner and his team are studying how hantaviruses persist in rodent hosts, such as deer mice without causing disease. Understanding this asymptomatic persistence is key to mitigating the risk of zoonotic spillover to humans. VIDO will establish one of only a few deer mouse colonies in North America, enabling researchers to analyze immune responses and virus behavior in these animals. This foundational research is essential for developing strategies to prevent future outbreaks.

In parallel, VIDO is advancing mRNA and protein subunit vaccine candidates for HPS. These vaccines hold the potential to protect populations from future hantavirus outbreaks and safeguard public health.



ADVANCING LASSA VIRUS RESEARCH TO PREVENT GLOBAL SPREAD

Lassa virus, endemic to West Africa, causes Lassa fever—a severe hemorrhagic disease that results in 300,000–500,000 cases and up to 5,000 deaths annually. The virus spreads primarily through contact with food or items contaminated by Mastomys natalensis rodents. Human-to-human transmission is possible, often leading to deadly outbreaks. Pregnant women face particularly high risks with maternal mortality exceeding 30% and fetal loss nearing 95%.

Due to its high mortality and potential for global spread, the WHO classifies Lassa virus as a priority pathogen for research and vaccine development.

As global travel and trade increase, the rise of Lassa virus spread grows, underscoring the need for better understanding this pathogen. VIDO's CL4 capacity will enable safe research on Lassa virus, paving the way for vaccine and novel therapeutic developments.



PIONEERING NEW FRONTIERS IN INFECTIOUS DISEASE RESEARCH

Conventional supercomputers struggle to predict how parts of pathogens connect with immune cells, slowing down vaccine development. Quantum computing, however, can analyze many possibilities at once, making the process faster and more accurate. This ability could help design better vaccines more efficiently.

Increasing readiness for the next pandemic will require a significant streamlining of current design processes for effective vaccines and therapeutics. Response will have to be much faster (to meet the WHO/CEPI 100-day target), highly flexible, and deployable across a broad range of potential threats including currently unknown pathogens (pathogen X). Dr. Gordon Broderick's team at VIDO, and Dr. Steven Rayan from USask's Centre for Quantum Topology and Its Applications (quanTA) are partnering to harness the latest advances in computational approaches to streamline vaccine development.

As a beta project, they are using quantum computing to understand how proteins from the Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) interact with immune cells in pigs. This research aims to accelerate vaccine development for infectious diseases by evaluating candidate vaccine components with unprecedented speed and precision.

Simultaneously, generative AI is being applied at VIDO to model how tuberculosis persists, offering insights into potential new treatments. These innovative technologies are set to revolutionize how we approach complex infectious diseases.

COMBATING LYME DISEASE

Lyme disease is caused by the bacterium Borrelia burgdorferi and is the most common tick-borne illness in North America. It is transmitted to humans and animals through bites from blacklegged ticks, leading to symptoms that can impact multiple systems in the body.

As temperatures rise, blacklegged ticks are expanding their range into regions that were once too cold for them to survive and Lyme disease is spreading. In 2022, there were over 2,500 reported cases in Canada.

Dr. Jenny Wachter's team is exploring the unique biology of Borrelia burgdorferi to understand how it thrives in both ticks and animal hosts. They are investigating how the bacteria survives and spreads, focusing on its genetic makeup and the role of viruses that interact with it. This research is crucial for identifying new ways to stop Lyme disease from spreading and developing more effective vaccines and treatments to protect both humans and animals.

MITIGATING THE THREAT OF HIGH-PATH AVIAN INFLUENZA

High-path avian influenza (HPAI), also known as "H5N1", has raised global concerns due to its potential to spread across species, including its recent infection of dairy cattle in the U.S. This marked the first time H5N1 has been reported in cattle, which increases the risk of further transmission to other mammals including humans. Controlling H5N1 in birds and animals is a key strategy in the global effort to manage H5N1spread.

VIDO scientists Dr. Yan Zhou, Dr. Antonio Facciuolo and Dr. Bryce Warner are focusing on understanding how HPAI infects dairy cattle. Using VIDO's high-containment facilities, the team mimicked natural infection by introducing the virus into cows' udders, replicating how contaminated milking equipment could spread H5N1. The infected cows developed mastitis and showed reduced milk production, consistent with outbreaks on U.S. dairy farms. However, these cows were protected from re-infection, strongly suggesting that a vaccination strategy could prevent infection in dairy cattle. VIDO's research aims to contribute to global efforts in controlling H5N1 and preventing its spread to other animals and humans.

Furthermore, VIDO is collaborating with other research centres worldwide, including Friedrich-Loeffler-Institut (FLI) in Germany, and members of the RAV3N network including Ohio State University, Biosecurity Research Institute (BRI) in Kansas, and the U.S. Department of Agriculture (USDA) in Iowa, to share data and advance efforts in understanding the disease.



PIONEERING BROADLY PROTECTIVE VACCINES

VIDO is advancing vaccine development with a platform technology it has termed the "train model," which teaches the immune system to recognize key features (called antigens) found within different viruses. This approach aims to create broadly protective vaccines for both existing and emerging pathogens.

Broadly protective vaccines are essential for pandemic preparedness as they can provide protection against more than one virus, even those that have not yet jumped into humans. As viruses mutate or jump between species, they can change in ways that evade immunity. The train model addresses this challenge by incorporating immunity inducing components of different viruses all within one vaccine, enabling protection across a wide range of pathogens. Should a new pathogen emerge in the human population for which VIDO has developed a broadly protective vaccine, we will be able to deploy this vaccine quickly and hopefully prevent another pandemic.

VIDO's work in this area is critical for strengthening pandemic preparedness. By developing vaccines that can protect against entire families of viruses, VIDO is helping to build a safer future and reducing the global impact of infectious diseases. This innovative work, supported by a $24 million investment by CEPI, positions VIDO as a leader in advancing next-generation vaccines that can safeguard public health on a global scale.

WORLD-LEADING CONTAINMENT FACILITIES AND CAPACITY

VIDO has some of the most advanced containment infrastructure in the world to support infectious disease research and vaccine development for humans and animals. From bats to bison, VIDO can house a range of animals in its containment levels 2 and 3-Ag facility.

To strengthen Canada's preparedness for emerging infectious diseases, VIDO is enhancing its infrastructure and capabilities. Key aspects include a new manufacturing facility, establishing containment level 4 (CL4) capacity and building new CL2 animal housing that can hold a variety of exotic species.

STRENGTHENING CANADA'S VACCINE MANUFACTURING CAPACITY

VIDO's vaccine development centre (VDC) is a state-of-the-art biomanufacturing facility built to Good Manufacturing Practice (GMP) quality standards and capable of operating at Containment Level 3 (CL3). The facility is positioned to play a critical role in boosting Canada's vaccine manufacturing capacity.

By increasing domestic vaccine manufacturing, VIDO's facility strengthens the nation's preparedness for future pandemics and emerging infectious diseases helping safeguard Canada's health and food security.

This facility is already booked over a year in advance with diverse projects including:

- Development of an mRNA vaccine for fish
- Development of a recombinant protein antigen vaccine for cattle in Africa
- Development of an attenuated bacterial vaccine for pigs
- CEPI-funded project advancing a pan-sarbecovirus vaccine toward Phase I clinical trials, including regulated process development, scale-up, and manufacturing

VIDO's VDC leverages world-class research infrastructure to accelerate vaccine development for both humans and animals. As part of Canada's Biomanufacturing and Life Sciences Strategy, it enhances national capacity and solidifies VIDO's position as a fully integrated centre for infectious disease research, vaccine development, and manufacturing.

UPGRADING CONTAINMENT

As part of VIDO's preparation to be able to respond to any pathogen, a portion of its containment level 3 agriculture (CL3-Ag) facility will be upgraded to CL4, the highest level of containment. Once complete, VIDO will be the only non-government CL4 facility in Canada. This critical expansion will double Canada's CL4 research capacity, enabling VIDO scientists to safely study and develop countermeasures for all of the world's pathogens.



Ebola virus. photo credit: National Institute of Allergy and Infectious Diseases, National Institutes of Health.



CL4 allows work with pathogens that pose a high risk to the health of people working with them, and a high risk to public health. These pathogens are likely to cause serious disease and effective treatment and vaccines are usually not available.

Examples: Nipah virus, Hendra virus, tick-borne encephalitis virus

CL3 allows work with pathogens that may cause serious disease to people working with them, and low risk to public health. Effective treatment and vaccines are usually available.

Examples: tuberculosis, SARS-CoV-2, anthrax, rabies, West Nile virus

CL2 allows work with pathogens that pose moderate risk to people working with them, and low risk to public health.

Examples: common cold viruses, seasonal flu, salmonella

CL1 describes basic high school and university undergraduate labs for work with pathogens not capable of causing disease, or unlikely to do so.

Examples: skin bacteria, brewer's yeast

NEW ANIMAL HOUSING CAPACITY

VIDO is constructing a new animal housing facility that will greatly enhance research capacity, ensuring that VIDO continues to play a key role in human and animal vaccine development. Through significant funding (Government of Canada, Government of Saskatchewan, City of Saskatoon, 'Friends of VIDO'), a new containment level 2-Ag (CL2-Ag) animal facility is under construction that will greatly enhance research capacity. This new facility will be over six times larger than the original facility and have the capability of housing a broader range of animals, including bats and insects, which are often linked to new outbreaks. The new facility will also offer increased enrichment opportunities for the animals.

A key aspect of these upgrades is building local awareness, understanding and support. To do this, VIDO has conducted several engagements with the local community and plans to continue doing so.

Minister of Innovation, Science and Industry François-Philippe Champagne visited VIDO in April 2024.

Canada's Ambassador to the Republic of Korea, Tamara Mawhinney, with VIDO Director of Operations Paul Hodgson.

VIDO received a $24 million (CAD) grant from CEPI to support its vaccine development and global pandemic preparedness work.

VIDO joins the INTERCEPTOR project, strengthening international collaboration in high-containment research and pandemic response.

VIDO CEO Dr. Volker Gerdts with Senator Tracy Muggli during her visit to the organization.

BUSINESS DEVELOPMENT & STRATEGIC PARTNERSHIPS

This year, VIDO continued to expand its contractual and strategic partnerships. The organization signed nine contract research agreements, and the Vaccine Development Centre completed its first external development and manufacturing contract. Several major projects are already scheduled for 2026, reflecting continued demand for VIDO's specialized capabilities. Clients consistently praised the quality of the research, clear communication, and well-managed studies, with several providing referrals to new partners. To support future planning, the Business Development team introduced a new system to identify and prioritize projects based on market need and strategic value. The team also strengthened external connections through key meetings at BIO in San Diego and the World Vaccine Congress in Washington DC.

Strategic partnerships remain central to VIDO's global impact and reputation and continue to grow. A $24 million investment from the Coalition for Epidemic Preparedness Innovations (CEPI) is supporting development of a broadly protective coronavirus vaccine. VIDO also joined INTERCEPTOR, a European-centred network advancing high-containment research. VIDO maintains a strong presence in the U.S.-based RAV3N network, contributing its first RAV3N publication with VIDO authors. A key aspect of these partnerships and networks is to extend VIDO's influence and strengthen its role in protecting human and animal health.

Funding

VIDO conducts leading-edge research and establishes infrastructure to improve preparedness for the next pandemic thanks to the long-term support from a diverse group of stakeholders.

VIDO receives funding support from federal, provincial, and municipal governments, the livestock industry, foundations, human and animal health companies, and private and corporate donors. We are proud to highlight our philanthropic "Friends of VIDO" donors on page 24 and other contributors on the inside of the back cover. Importantly, the benefit of this support goes beyond research and development and the vaccines commercialized.

> Overall revenue has increased by 75% this year compared to 2023-2024.

Funding received was due to new research grants, contract research and investments supporting growth as VIDO becomes Canada's Centre for Pandemic Research. VIDO recognized revenue of $36.2 million from PrairiesCan for the creation of infrastructure related to this project. A large increase in donation revenue this fiscal year due to the accounting recognition of several years of contributions in this one year. VIDO's expenses have also increased by 58% over the previous year primarily due to the timing of expenditures of the ongoing infrastructure projects.

VIDO would like to thank its contributors, in particular the 'Friends of VIDO', for supporting its team, research, and infrastructure upgrades as the organization continues to strengthen its impact in Canada and abroad.

- **60%** Federal
- **22%** Non-Government, CEPI, and contract research
- **9%** Donations
- **6%** Provincial
- **3%** Other Funding

- **49%** Investment in Infrastructure
- **25%** Salaries and Benefits
- **18%** Materials and Supplies
- **3%** Capital Assets
- **2%** Utilities
- **2%** Maintenance
- **1%** Travel and Recruiting

FRIENDS OF VIDO

The Friends of VIDO campaign has continued to grow, thanks to the remarkable generosity of individuals and organizations who share VIDO's commitment to protecting global health. These valued supporters are helping accelerate progress against emerging infectious diseases and prepare for the pandemics of tomorrow.

Their contributions are making a meaningful difference—enabling investments in cutting-edge equipment, infrastructure upgrades, advanced training programs, and the recruitment of top global scientific talent through research chairs and fellowships.

Join this dedicated community and help shape the future of infectious disease research.

View our complete list of donations or donate at vido.org/donate

ANNUAL DONOR ROLL

The following list recognizes the donations committed or received May 1, 2024 - April 30, 2025.

$10,000-$99,999

Leo Bourassa & Daphne Arnason

Jack & Shirley Brodsky

Don Ching & Darien Moore

Linda & Lyle Garratt

Dailene Kells

2 anonymous donors

$1,000-$9,999

Borstmayer Ventures Ltd.

Bob & Kathy Burnyeat

Robin Chapman

Grant Cheston

Community Club

Dr. Barb Eatock

Gerry Griffiths

John & Marie Gormley

David & Laurel Kelly

Peter Kneeland

Rory McAlpine

Garnet Packota

Hertha Pfeifer

Pratus Ag Ltd

Lynne Samson

Gord Stewart & Maria Styacko

St. Gregor Co-operative

Lloyd & Shirley Widenmaier

UNDER $1,000

Andrea Baker

David Baker

Toni & Dennis Beerling

Bill Black

June L. Blau

Marilyn Bodner

Linda Charlton

Joan Collins

Clinton & Sylvia Cory

Stacey Griffin

Jan-Mark and Sharon Gustafson

Elizabeth Hampson

Robert & Claire Hart

Melissa Haveroen

Shelby Haque

Vern Kiefer

Nancy Kot

Susan Leitch

Ivy McGrath

Leslie McGrath

Lynne Nieman

Leona Schemenauer

Greg and Rae Smith

Lionel Stehr

Dr. Gerard & Arpine Tertzakian

Alan Thomarat

Faye Way

5 anonymous donors

2024-2025 CONTRIBUTORS

AbCellera

Agriculture and Agri-Food Canada

Alberta Beef Producers

Alberta Conservation Association

Alberta Milk

Alberta Pork

AnGes

Attenubiotics

Beef Cattle Research Council

Boston Children's Hospital

Canada Foundation for Innovation

Canadian Institutes of Health Research
Natural Sciences and Engineering Research Council

Canadian Swine Research and Development Cluster

Chicken Farmers of Saskatchewan

Coalition for Epidemic Preparedness Innovations

College of Medicine

Cytophage

Egg Farmers of Canada

Globalink Research Award

Government of Alberta

Government of Canada

Government of Saskatchewan

Government of the United States

Guangzhou Yuanbo Medical Tech Co.

Harvard University

Immune Biosolutions Inc.

Innovation Saskatchewan

Institut Jules Bordet

International Development Research Centre

Jarislowsky Chair in Biotechnology Management

Kamloops Stockmen's Association

KreaMedica

Living Skies

Mayo Clinic

Ministry of Agriculture

Ministry of Environment

Mitacs

Modulant Bio

National Institutes of Health

New Frontiers Research Fund

Parks Canada

Pennsylvania State University

PrairiesCan

Public Health Agency of Canada
Promis

Research Institute of McGill University Health Centre

Respiratory Research Centre

Result Driven Agriculture Research (RDAR)

Saskatchewan Cattle Association

Saskatchewan Health Research Foundation

Saskatchewan Pork Development Board

SeaCure AG

Seppic

Social Sciences and Humanities Research Council

State University of New York

Sunnybrook Research Centre

Swine Innovation Porc

True North Bioscience

University of Alberta

University of British Columbia

University of Calgary

University of Guelph

University of Manitoba

University of Montana

University of Ottawa

University of Victoria

Vaccine Formulation Institute

Washington State University

Western College of Veterinary Medicine

VACCINE AND INFECTIOUS DISEASE ORGANIZATION
University of Saskatchewan 120 Veterinary Road
Saskatoon, SK S7N 5E3
Phone (CA): 306-966-7465
Email: info@vido.org